A breast one-patient panel of heterogeneous genomes reveals genetic alterations driving DCIS into invasive lesions

Future Oncol. 2019 May;15(14):1565-1576. doi: 10.2217/fon-2018-0555. Epub 2019 Mar 19.

Abstract

Aim: Utilize breast cancer samples in the same patient to indicate breast cancer development. Patients & methods: We performed whole-exome analysis of spatially independent ductal carcinoma in situ (DCIS) and invasive ductal carcinoma samples from the same breast. Results: In VEGF pathway, we observed two genes disrupted in DCIS, while another four (including ACTN2) mutated in invasive ductal carcinoma. When looked up TCGA database, we identified seven breast cancer patients with ACTN2 somatic mutations and observed a dramatic decrease in the overall survival time in ACTN2 mutant patients (p = 0.0182). A further finding in the TCGA database shows that breast cancer patients with ≥2 mutated genes in VEGF pathways showed worse prognosis (p = 0.0013). Conclusion: TCGA database and special case could inform each other to reveal DCIS developmental rules.

Keywords: ACTN mutation; VEGF pathway; ductal carcinoma; invasive ductal carcinoma; precision medicine.

MeSH terms

  • Actinin / genetics
  • Adult
  • Biomarkers, Tumor
  • Breast Neoplasms / diagnosis
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / mortality
  • Carcinoma, Intraductal, Noninfiltrating / diagnosis
  • Carcinoma, Intraductal, Noninfiltrating / genetics*
  • Carcinoma, Intraductal, Noninfiltrating / metabolism
  • DNA Copy Number Variations
  • Exome Sequencing
  • Female
  • Genetic Heterogeneity*
  • Genetic Variation*
  • Genomics* / methods
  • Humans
  • Mammography / methods
  • Middle Aged
  • Mutation
  • Neoplasm Invasiveness
  • Precision Medicine
  • Prognosis
  • Signal Transduction
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • ACTN2 protein, human
  • Biomarkers, Tumor
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Actinin